1
|
Thompson KN, Ju JA, Ory EC, Pratt SJP, Lee RM, Mathias TJ, Chang KT, Lee CJ, Goloubeva OG, Bailey PC, Chakrabarti KR, Jewell CM, Vitolo MI, Martin SS. Microtubule disruption reduces metastasis more effectively than primary tumor growth. Breast Cancer Res 2022; 24:13. [PMID: 35164808 PMCID: PMC8842877 DOI: 10.1186/s13058-022-01506-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2020] [Accepted: 01/26/2022] [Indexed: 12/04/2022] Open
Abstract
Clinical cancer imaging focuses on tumor growth rather than metastatic phenotypes. The microtubule-depolymerizing drug, Vinorelbine, reduced the metastatic phenotypes of microtentacles, reattachment and tumor cell clustering more than tumor cell viability. Treating mice with Vinorelbine for only 24 h had no significant effect on primary tumor survival, but median metastatic tumor survival was extended from 8 to 30 weeks. Microtentacle inhibition by Vinorelbine was also detectable within 1 h, using tumor cells isolated from blood samples. As few as 11 tumor cells were sufficient to yield 90% power to detect this 1 h Vinorelbine drug response, demonstrating feasibility with the small number of tumor cells available from patient biopsies. This study establishes a proof-of-concept that targeted microtubule disruption can selectively inhibit metastasis and reveals that existing FDA-approved therapies could have anti-metastatic actions that are currently overlooked when focusing exclusively on tumor growth.
Collapse
|
2
|
Reader JC, Fan C, Ory ECH, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM. Microtentacle Formation in Ovarian Carcinoma. Cancers (Basel) 2022; 14:cancers14030800. [PMID: 35159067 PMCID: PMC8834106 DOI: 10.3390/cancers14030800] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 01/16/2022] [Accepted: 01/19/2022] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND The development of chemoresistance to paclitaxel and carboplatin represents a major therapeutic challenge in ovarian cancer, a disease frequently characterized by malignant ascites and extrapelvic metastasis. Microtentacles (McTNs) are tubulin-based projections observed in detached breast cancer cells. In this study, we investigated whether ovarian cancers exhibit McTNs and characterized McTN biology. METHODS We used an established lipid-tethering mechanism to suspend and image individual cancer cells. We queried a panel of immortalized serous (OSC) and clear cell (OCCC) cell lines as well as freshly procured ascites and human ovarian surface epithelium (HOSE). We assessed by Western blot β-tubulin isotype, α-tubulin post-translational modifications and actin regulatory proteins in attached/detached states. We studied clustering in suspended conditions. Effects of treatment with microtubule depolymerizing and stabilizing drugs were described. RESULTS Among cell lines, up to 30% of cells expressed McTNs. Four McTN morphologies (absent, symmetric-short, symmetric-long, tufted) were observed in immortalized cultures as well as ascites. McTN number/length varied with histology according to metastatic potential. Most OCCC overexpressed class III ß-tubulin. OCCC/OSC cell lines exhibited a trend towards more microtubule-stabilizing post-translational modifications of α-tubulin relative to HOSE. Microtubule depolymerizing drugs decreased the number/length of McTNs, confirming that McTNs are composed of tubulin. Cells that failed to form McTNs demonstrated differential expression of α-tubulin- and actin-regulating proteins relative to cells that form McTNs. Cluster formation is more susceptible to microtubule targeting agents in cells that form McTNs, suggesting a role for McTNs in aggregation. CONCLUSIONS McTNs likely participate in key aspects of ovarian cancer metastasis. McTNs represent a new therapeutic target for this disease that could refine therapies, including intraperitoneal drug delivery.
Collapse
Affiliation(s)
- Jocelyn C. Reader
- Division of Gynecologic Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (J.C.R.); (C.F.); (P.S.); (M.M.N.C.); (G.G.R.)
- Department of Pharmaceutical Sciences, School of Pharmacy and Health Sciences, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA
| | - Cong Fan
- Division of Gynecologic Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (J.C.R.); (C.F.); (P.S.); (M.M.N.C.); (G.G.R.)
| | - Eleanor Claire-Higgins Ory
- Department of Physiology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (E.C.-H.O.); (J.J.); (R.L.)
| | - Julia Ju
- Department of Physiology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (E.C.-H.O.); (J.J.); (R.L.)
| | - Rachel Lee
- Department of Physiology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (E.C.-H.O.); (J.J.); (R.L.)
| | - Michele I. Vitolo
- Department of Pharmacology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (M.I.V.); (S.S.M.)
| | - Paige Smith
- Division of Gynecologic Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (J.C.R.); (C.F.); (P.S.); (M.M.N.C.); (G.G.R.)
| | - Sulan Wu
- Department of Chemistry and Biochemistry, Oberlin College, Oberlin, OH 44074, USA;
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA
| | - Mc Millan Nicol Ching
- Division of Gynecologic Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (J.C.R.); (C.F.); (P.S.); (M.M.N.C.); (G.G.R.)
- Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
- Division of Cancer Imaging, Russel H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Hospital, Baltimore, MD 21287, USA
| | - Emmanuel B. Asiedu
- Department of Microbiology and Immunology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (E.B.A.); (T.J.W.)
| | - Christopher M. Jewell
- Fischell Department of Bioengineering, University of Maryland College Park, College Park, MD 20742, USA; (C.M.J.); (H.-C.H.)
- Baltimore Veterans Administration Medical Center, Baltimore, MD 21201, USA;
| | - Gautam G. Rao
- Division of Gynecologic Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (J.C.R.); (C.F.); (P.S.); (M.M.N.C.); (G.G.R.)
| | - Amy Fulton
- Baltimore Veterans Administration Medical Center, Baltimore, MD 21201, USA;
- Department of Pathology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Tonya J. Webb
- Department of Microbiology and Immunology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (E.B.A.); (T.J.W.)
| | - Peixin Yang
- Department of Obstetrics, Gynecology & Reproductive Sciences and Biochemistry & Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA;
| | - Alessandro D. Santin
- Division of Gynecologic Oncology, Smilow Cancer Center, Yale University, New Haven, CT 06520, USA;
| | - Huang-Chiao Huang
- Fischell Department of Bioengineering, University of Maryland College Park, College Park, MD 20742, USA; (C.M.J.); (H.-C.H.)
| | - Stuart S. Martin
- Department of Pharmacology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (M.I.V.); (S.S.M.)
- Department of Pathology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Dana M. Roque
- Division of Gynecologic Oncology, Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; (J.C.R.); (C.F.); (P.S.); (M.M.N.C.); (G.G.R.)
- Correspondence:
| |
Collapse
|
3
|
Bhandary L, Bailey PC, Chang KT, Underwood KF, Lee CJ, Whipple RA, Jewell CM, Ory E, Thompson KN, Ju JA, Mathias TM, Pratt SJP, Vitolo MI, Martin SS. Lipid tethering of breast tumor cells reduces cell aggregation during mammosphere formation. Sci Rep 2021; 11:3214. [PMID: 33547369 PMCID: PMC7865010 DOI: 10.1038/s41598-021-81919-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Accepted: 12/24/2020] [Indexed: 12/11/2022] Open
Abstract
Mammosphere assays are widely used in vitro to identify prospective cancer-initiating stem cells that can propagate clonally to form spheres in free-floating conditions. However, the traditional mammosphere assay inevitably introduces cell aggregation that interferes with the measurement of true mammosphere forming efficiency. We developed a method to reduce tumor cell aggregation and increase the probability that the observed mammospheres formed are clonal in origin. Tethering individual tumor cells to lipid anchors prevents cell drift while maintaining free-floating characteristics. This enables real-time monitoring of single tumor cells as they divide to form mammospheres. Monitoring tethered breast cancer cells provided detailed size information that correlates directly to previously published single cell tracking data. We observed that 71% of the Day 7 spheres in lipid-coated wells were between 50 and 150 μm compared to only 37% in traditional low attachment plates. When an equal mixture of MCF7-GFP and MCF7-mCherry cells were seeded, 65% of the mammospheres in lipid-coated wells demonstrated single color expression whereas only 32% were single-colored in low attachment wells. These results indicate that using lipid tethering for mammosphere growth assays can reduce the confounding factor of cell aggregation and increase the formation of clonal mammospheres.
Collapse
Affiliation(s)
- Lekhana Bhandary
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA
| | - Patrick C Bailey
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA.,Graduate Program in Biochemistry, University of Maryland School of Medicine, 800 W. Baltimore St., Baltimore, MD, 21201, USA
| | - Katarina T Chang
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA.,Graduate Program in Life Sciences, University of Maryland School of Medicine, 800 W. Baltimore St., Baltimore, MD, 21201, USA
| | - Karen F Underwood
- UMGCCC Flow Cytometry Shared Service, 655 West Baltimore Street, BRB 7-022, Baltimore, MD, 21201, USA
| | - Cornell J Lee
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA
| | - Rebecca A Whipple
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA
| | - Christopher M Jewell
- Fischell Department of Bioengineering, 3102 A. James Clark Hall, College Park, MD, 20742, USA
| | - Eleanor Ory
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA
| | - Keyata N Thompson
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA
| | - Julia A Ju
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA
| | - Trevor M Mathias
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA
| | - Stephen J P Pratt
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA.,Graduate Program in Biochemistry, University of Maryland School of Medicine, 800 W. Baltimore St., Baltimore, MD, 21201, USA
| | - Michele I Vitolo
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA. .,Graduate Program in Biochemistry, University of Maryland School of Medicine, 800 W. Baltimore St., Baltimore, MD, 21201, USA. .,Department of Physiology, University of Maryland School of Medicine, 655 W. Baltimore St., Baltimore, MD, 21201, USA.
| | - Stuart S Martin
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMGCCC), 22 S. Greene St., Baltimore, MD, 21201, USA. .,Graduate Program in Biochemistry, University of Maryland School of Medicine, 800 W. Baltimore St., Baltimore, MD, 21201, USA. .,Department of Physiology, University of Maryland School of Medicine, 655 W. Baltimore St., Baltimore, MD, 21201, USA. .,, Bressler Research Building Room 10-29, 655 West Baltimore Street, Baltimore, MD, 21201, USA.
| |
Collapse
|
4
|
Ju JA, Lee CJ, Thompson KN, Ory EC, Lee RM, Mathias TJ, Pratt SJP, Vitolo MI, Jewell CM, Martin SS. Partial thermal imidization of polyelectrolyte multilayer cell tethering surfaces (TetherChip) enables efficient cell capture and microtentacle fixation for circulating tumor cell analysis. LAB ON A CHIP 2020; 20:2872-2888. [PMID: 32744284 PMCID: PMC7595763 DOI: 10.1039/d0lc00207k] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
The technical challenges of imaging non-adherent tumor cells pose a critical barrier to understanding tumor cell responses to the non-adherent microenvironments of metastasis, like the bloodstream or lymphatics. In this study, we optimized a microfluidic device (TetherChip) engineered to prevent cell adhesion with an optically-clear, thermal-crosslinked polyelectrolyte multilayer nanosurface and a terminal lipid layer that simultaneously tethers the cell membrane for improved spatial immobilization. Thermal imidization of the TetherChip nanosurface on commercially-available microfluidic slides allows up to 98% of tumor cell capture by the lipid tethers. Importantly, time-lapse microscopy demonstrates that unique microtentacles on non-adherent tumor cells are rapidly destroyed during chemical fixation, but tethering microtentacles to the TetherChip surface efficiently preserves microtentacle structure post-fixation and post-blood isolation. TetherChips remain stable for more than 6 months, enabling shipment to distant sites. The broad retention capability of TetherChips allows comparison of multiple tumor cell types, revealing for the first time that carcinomas beyond breast cancer form microtentacles in suspension. Direct integration of TetherChips into the Vortex VTX-1 CTC isolation instrument shows that live CTCs from blood samples are efficiently captured on TetherChips for rapid fixation and same-day immunofluorescence analysis. Highly efficient and unbiased label-free capture of CTCs on a surface that allows rapid chemical fixation also establishes a streamlined clinical workflow to stabilize patient tumor cell samples and minimize analytical variables. While current studies focus primarily on CTC enumeration, this microfluidic device provides a novel platform for functional phenotype testing in CTCs with the ultimate goal of identifying anti-metastatic, patient-specific therapies.
Collapse
Affiliation(s)
- Julia A Ju
- Marlene and Stewart Greenebaum NCI Comprehensive Cancer Center, University of Maryland School of Medicine, Bressler Research Building Rm 10-29, 655 W, Baltimore St., Baltimore, MD 21201, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Suspension State Promotes Drug Resistance of Breast Tumor Cells by Inducing ABCC3 Overexpression. Appl Biochem Biotechnol 2019; 190:410-422. [PMID: 31367898 DOI: 10.1007/s12010-019-03084-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 07/05/2019] [Indexed: 12/19/2022]
Abstract
Mechanical microenvironment plays a critical role in cancer drug resistance and this study supposed that suspension state might be involved in drug resistance of breast tumor cells. The viability of cell was detected by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Cell cycle and apoptosis were detected by flow cytometry. Gene and protein were tested by RT-qPCR and Western blot, respectively. Drug resistance of MDA-MB-231 cells cultured for 72 h under suspension state was significantly increased. Suspension state was found to induce the overexpression of adenosine triphosphate-binding cassette subfamily C member 3 (ABCC3) in MDA-MB-231 cells. Silencing of ABCC3 significantly decreased drug resistance of suspension MDA-MB-231 cells. Moreover, suspension state was able to increase lamin A/C accumulation in MDA-MB-231 cells and lamin A/C regulated the expression of ABCC3. Moreover, lamin A/C knockdown also decreased drug resistance of suspension MDA-MB-231 cells, but the effect on drug resistance was less than that of ABCC3 knockdown. Suspension state plays a vital role in promoting drug resistance of MDA-MB-231 cells by inducing ABCC3 overexpression, and lamin A/C accumulation is associated with this process.
Collapse
|
6
|
Tang T, Weng T, Jia H, Luo S, Xu Y, Li L, Zhang P. Harnessing the layer-by-layer assembly technique to design biomaterials vaccines for immune modulation in translational applications. Biomater Sci 2019; 7:715-732. [PMID: 30762040 DOI: 10.1039/c8bm01219a] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The existence of challenging diseases such as cancers, HIV and Zika requires developing new vaccines that can generate tunable and robust immune responses against the diseases. Biomaterials-based techniques have been broadly explored for designing vaccines that can produce controllable and potent immunity. Among the existing biomaterials-based strategies, the layer-by-layer (LbL) assembly technique is remarkably attractive in vaccine design due to its unique features such as programmed and versatile cargo loading, cargo protection, co-delivery, juxtaposing of immune signals, etc. In this work, we reviewed the existing LbL-based vaccine design techniques for translational applications. Specifically, we discussed nanovaccines constructed by coating polyelectrolyte multilayers (PEMs) on nanoparticles, microcapsule vaccines assembled from PEMs, polyplex/complex vaccines condensed from charged materials and microneedle vaccines deposited with PEMs, highlighting the employment of these techniques to promote immunity against diseases ranging from cancers to infectious and autoimmune diseases (i.e., HIV, influenza, multiple sclerosis, etc.). Additionally, the review specifically emphasized using LbL-based vaccine technologies for tuning the cellular and molecular pathways, demonstrating the unique advantages presented by these vaccination strategies. These studies showed the versatility and potency of using LbL-based techniques for designing the next generation of biomaterials vaccines for translational purposes.
Collapse
Affiliation(s)
- Tan Tang
- Department of Material Processing and Controlling, School of Mechanical Engineering & Automation, Beihang University, China.
| | | | | | | | | | | | | |
Collapse
|
7
|
Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology. Cells 2019; 8:cells8060553. [PMID: 31174404 PMCID: PMC6627072 DOI: 10.3390/cells8060553] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 05/31/2019] [Accepted: 06/03/2019] [Indexed: 01/01/2023] Open
Abstract
Circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) have been shown to correlate negatively with patient survival. Actual CTC counts before and after treatment can be used to aid in the prognosis of patient outcomes. The presence of circulating tumor materials (CTMat) can advertise the presence of metastasis before clinical presentation, enabling the early detection of relapse. Importantly, emerging evidence is indicating that cancer treatments can actually increase the incidence of CTCs and metastasis in pre-clinical models. Subsequently, the study of CTCs, their biology and function are of vital importance. Emerging technologies for the capture of CTC/CTMs and CTMat are elucidating vitally important biological and functional information that can lead to important alterations in how therapies are administered. This paves the way for the development of a "liquid biopsy" where treatment decisions can be informed by information gleaned from tumor cells and tumor cell debris in the blood.
Collapse
|
8
|
Ory EC, Chen D, Chakrabarti KR, Zhang P, Andorko JI, Jewell CM, Losert W, Martin SS. Extracting microtentacle dynamics of tumor cells in a non-adherent environment. Oncotarget 2017; 8:111567-111580. [PMID: 29340075 PMCID: PMC5762343 DOI: 10.18632/oncotarget.22874] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Accepted: 11/15/2017] [Indexed: 12/12/2022] Open
Abstract
During metastasis, tumor cells dynamically change their cytoskeleton to traverse through a variety of non-adherent microenvironments, including the vasculature or lymphatics. Due to the challenges of imaging drift in non-adhered tumor cells, the dynamic cytoskeletal phenotypes are poorly understood. We present a new approach to analyze the dynamic cytoskeletal phenotypes of non-adhered cells that support microtentacles (McTNs), which are cell surface projections implicated in metastatic reattachment. Combining a recently-developed cell tethering method with a novel image analysis framework allowed McTN attribute extraction. Full cell outlines, number of McTNs, and distance of McTN tips from the cell body boundary were calculated by integrating a rotating anisotropic filtering method for identifying thin features with retinal segmentation and active contour algorithms. Tethered cells behave like free-floating cells; however tethering reduces cell drift and improves the accuracy of McTN measurements. Tethering cells does not significantly alter McTN number, but rather allows better visualization of existing McTNs. In drug treatment experiments, stabilizing tubulin with paclitaxel significantly increases McTN length, while destabilizing tubulin with colchicine significantly decreases McTN length. Finally, we quantify McTN dynamics by computing the time delay autocorrelations of 2 composite phenotype metrics (cumulative McTN tip distance, cell perimeter:cell body ratio). Our automated analysis demonstrates that treatment with paclitaxel increases total McTN amount and colchicine reduces total McTN amount, while paclitaxel also reduces McTN dynamics. This analysis method enables rapid quantitative measurement of tumor cell drug responses within non-adherent microenvironments, using the small numbers of tumor cells that would be available from patient samples.
Collapse
Affiliation(s)
- Eleanor C. Ory
- Department of Physics, IPST, and IREAP, University of Maryland, College Park, MD 20742, USA
- Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Desu Chen
- Department of Physics, IPST, and IREAP, University of Maryland, College Park, MD 20742, USA
| | - Kristi R. Chakrabarti
- Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
- Program in Molecular Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Peipei Zhang
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA
| | - James I. Andorko
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA
| | - Christopher M. Jewell
- Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
- Fischell Department of Bioengineering, University of Maryland, College Park, MD 20742, USA
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
- United States Department of Veterans Affairs, Baltimore, MD 21201, USA
| | - Wolfgang Losert
- Department of Physics, IPST, and IREAP, University of Maryland, College Park, MD 20742, USA
- Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Stuart S. Martin
- Marlene and Stewart Greenebaum NCI Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
- Department of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| |
Collapse
|
9
|
Zhang P, Bookstaver ML, Jewell CM. Engineering Cell Surfaces with Polyelectrolyte Materials for Translational Applications. Polymers (Basel) 2017; 9:E40. [PMID: 30970718 PMCID: PMC6431965 DOI: 10.3390/polym9020040] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2016] [Revised: 01/18/2017] [Accepted: 01/19/2017] [Indexed: 11/16/2022] Open
Abstract
Engineering cell surfaces with natural or synthetic materials is a unique and powerful strategy for biomedical applications. Cells exhibit more sophisticated migration, control, and functional capabilities compared to nanoparticles, scaffolds, viruses, and other engineered materials or agents commonly used in the biomedical field. Over the past decade, modification of cell surfaces with natural or synthetic materials has been studied to exploit this complexity for both fundamental and translational goals. In this review we present the existing biomedical technologies for engineering cell surfaces with one important class of materials, polyelectrolytes. We begin by introducing the challenges facing the cell surface engineering field. We then discuss the features of polyelectrolytes and how these properties can be harnessed to solve challenges in cell therapy, tissue engineering, cell-based drug delivery, sensing and tracking, and immune modulation. Throughout the review, we highlight opportunities to drive the field forward by bridging new knowledge of polyelectrolytes with existing translational challenges.
Collapse
Affiliation(s)
- Peipei Zhang
- Fischell Department of Bioengineering, University of Maryland, College Park, MA 20742, USA.
| | - Michelle L Bookstaver
- Fischell Department of Bioengineering, University of Maryland, College Park, MA 20742, USA.
| | - Christopher M Jewell
- Fischell Department of Bioengineering, University of Maryland, College Park, MA 20742, USA.
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MA 21201, USA.
- Marlene and Stewart Greenebaum Cancer Center, Baltimore, MA 21201, USA.
- United States Department of Veterans Affairs, Baltimore, MA 21201, USA.
| |
Collapse
|